stem

Specialty Please choose I’m not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health …

Competing interests HT received honoraria from AstraZeneca plc, Bristol Myers Squibb, Chugai Pharma, Janssen, Kyowa Kirin, Meiji Seika Pharma, Nippon Shinyaku, Mundipharma, Ono Pharmaceutical, SymBio pharmaceuticals, Takeda Pharmaceutical, Eisai, Fujimoto …

Highlights Roswell Park team prioritizes early movement to get patients home fasterLeukemia survivor credits quick recovery to regular physical activityApproach helps drive 100% 6-month survival for transplant recipients NOTE FOR …

UCI Health Chao Family Comprehensive Cancer Center is expanding treatment options for cancers of the blood or lymph systems with the launch of Orange County’s first adult bone marrow transplant …

A new antibody therapy developed at Stanford Medicine has shown that it can prepare patients for stem cell transplants without the need for toxic chemotherapy or radiation, according to results …

In this prospective study, we evaluated the trajectory of QoL and its specific domains in patients with hematological malignancies during their hospitalization for auto- and allo-HSCT. Our results showed that …

Elad S, Yarom N, Zadik Y, Kuten-Shorrer M, Sonis ST. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin. 2022;72:57–77. PubMed  …

Trial design This study will be a controlled, randomized clinical trial with an intervention period of 3 weeks (Fig. 1). The trial was registered at the Iranian Registry of Clinical Trials …

“Bone marrow or stem cell transplants are most commonly used in blood cancers, in which the bone marrow is full of malignant cells and patients have no other options,” Czechowicz …

Despite the exciting new therapies available for patients with blood cancers, both autologous and allogeneic stem cell transplants remain a powerful and necessary treatment modality. Dr Matthew Matasar, chief of …